The anti-obesity nutraceutical developed by the Central Marine Fisheries Research Institute (CMFRI) from seaweeds will soon hit the market.

The CMFRI has signed a pact with healthcare group VLCC for the commercial production of the product named Cadalmin Antihypercholesterolemic extract (Cadalmin - ACe), a natural remedy for obesity. A. Gopalakrishnan, director of CMFRI, signed a licence agreement with the director and executive vice president of the firm, said a release. Cadalmin was developed using natural marine bioactive ingredients from selected seaweeds.